Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2025; 17(8): 108845
Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.108845
Duodenal mucosal ablation by irreversible electroporation: Modulating the gut-liver axis in metabolic steatotic liver disease
Mariana M Ramírez-Mejía, Nahum Méndez-Sánchez
Mariana M Ramírez-Mejía, Plan of Combined Studies in Medicine, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04360, Mexico
Nahum Méndez-Sánchez, Liver Research Unit, Medica Sur Clinic and Foundation, Mexico City 14050, Mexico
Author contributions: Ramírez-Mejía MM was responsible for writing original draft, and visualization; Méndez-Sánchez N was responsible for conceptualization, supervision, writing review and editing; all of the authors read and approved the final version of the manuscript to be published.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Nahum Méndez-Sánchez, MD, MSc, PhD, AGAF, FAASLD, FACG, Liver Research Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, Col. Toriello Guerra, Mexico City 14050, Mexico. nah@unam.mx
Received: April 25, 2025
Revised: May 22, 2025
Accepted: July 25, 2025
Published online: August 27, 2025
Processing time: 125 Days and 7.6 Hours
Core Tip

Core Tip: Duodenal mucosal ablation (DMA) via irreversible electroporation has emerged as a novel strategy to modulate the gut–liver axis in metabolic dysfunction-associated steatotic liver disease (MASLD). In this letter, we analyzed recent preclinical evidence from Yu et al, who reported that DMA leads to reduced hepatic steatosis, improved lipid profiles, and enhanced intestinal barrier integrity. We contextualize these findings within the physiology of the duodenum and explore their translational potential as a minimally invasive therapeutic approach in MASLD.